关注公众号
收藏产品 产品详情
分子别名（Synonym）
ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1
表达区间及表达系统（Source）
Biotinylated Rat Her2 Protein, His,Avitag (HE2-R82E3) is expressed from human 293 cells (HEK293). It contains AA Thr 26 - Thr 656 (Accession # AAH61863.1).
Predicted N-terminus: Thr 26
Request for sequence蛋白结构（Molecular Characterization）
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 73.3 kDa. The protein migrates as 80-100 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
质量管理控制体系（QMS）
推荐产品
数据展示
电泳（SDS-PAGE）
Biotinylated Rat Her2 Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Biotinylated Rat Her2 Protein, His,Avitag (Cat. No. HE2-R82E3) is more than 90% and the molecular weight of this protein is around 70-100 kDa verified by SEC-MALS.
Report
用户评价 发表评论
背景介绍
Aberrant amplification or overexpression of the HER2/neu proto-oncogene is a key oncogenic driver. In breast cancer, approximately 25-30% of patients exhibit HER2 overexpression, leading to a more aggressive disease phenotype with faster growth, increased metastasis, and often reduced chemotherapy sensitivity. This correlates with poorer prognosis and makes HER2 a critical prognostic, predictive biomarker, and a major therapeutic target.
药物研发进展 
联系我们 
项目合作 